CDH17 and cancer: This also includes the so-called “cadherin switch” [11], generally associated with a worse clinical stage and a poor prognosis in cancer patients [48], and the acquisition of a mesenchymal metastatic phenotype in cancer cells that leave the epidermal layer [49,50].